Kamada : Results of Annual General Meeting of Shareholders held on December 28, 2023
December 28, 2023 at 08:10 pm IST
Share
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
For the Month of December 2023
Commission File Number 001-35948
Kamada Ltd.
(Translation of registrant's name into English)
2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F☒
Form 40-F☐
This Form 6-K is being incorporated by reference into the Registrant's Form S-8 Registration Statements, File Nos. 333-192720,333-207933,333-215983,333-222891,333-233267and 333-265866.
Other Information
On December 28, 2023, Kamada Ltd. (the "Company") held an Annual General Meeting of Shareholders at the Company's offices at 2 Holzman Street, Weizmann Science Park, Rehovot, Israel (the "Meeting"). At the Meeting, the shareholders voted on and approved, by the applicable required majority, each of the proposals that were described in the Company's Notice and Proxy Statement for the Meeting that was attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K furnished by the Company to the U.S. Securities and Exchange Commission on November 13, 2023. Accordingly, at the Meeting, the shareholders of the Company approved the following proposals:
The re-election of the following directors to serve as members of the Company's Board of Directors until the Company's next annual general meeting of shareholders and until their successors are duly elected by the shareholders of the Company:
Lilach Asher Topilsky Uri Botzer
Ishay Davidi Karnit Goldwasser Lilach Payorski Leon Recanati David Tsur
The increase in the base salary of Mr. Amir London, the Company's Chief Executive Officer.
The ratification and approval of the re-appointment of Kost Forer Gabbay & Kasierer, a member of Ernst& Young Global, as the Company's independent registered public accountants for the year ending December 31, 2023 and for such additional period until the Company's next annual general meeting of shareholders.
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 28, 2023
KAMADA LTD.
By: /s/ Nir Livneh
Nir Livneh
Vice President General Counsel and
Corporate Secretary
2
Attachments
Original Link
Original Document
Permalink
Disclaimer
Kamada Ltd. published this content on 28 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 December 2023 14:38:11 UTC.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.